For ER positive BC patients, classification followed by voting conducted with ≥90% sensitivity could likewise spare more recurrence-free patients unnecessary adjuvant systemic therapy using lncRNA compared to mRNA while achieving almost similar sensitivity (Table A2). Here, ESR1 is linked to breast cancer.